HIV AIDS Vaccines: 2007

Development of an HIV/AIDS vaccine has been slow because classical approaches to vaccine development have not yielded a vaccine. Encouragingly, new approaches using recombinant viral vectors, DNA vaccines, and combinations of different vectors in heterologous prime/boost regimens are yielding vaccines capable of controlling virulent immunodeficiency virus challenges in non‐human primate models. These new vaccines elicit T cells capable of recognizing and killing virus‐infected cells. Brief synopses are given for six vaccines currently advancing in human trials. Clinical Pharmacology & Therapeutics (2007) 82, 686–693; doi:10.1038/sj.clpt.6100408; published online 31 October 2007